세계 뼈성장 제품 시장 규모는 2023-2029년 연평균 3.72% 성장할 것으로 예상됩니다.
시장 기회와 촉진요인
자가발전형 이식형 장비의 부상
침습적 골성장 자극기는 골 형성을 유도하고 성장을 촉진하며 치유를 촉진하기 위해 치유되지 않은 골절 및 골 유합 부위에 전기 에너지를 공급하는 이식형 장치입니다. 이 장치는 이식된 리드를 통해 공급되는 직류 전류를 사용하여 골절 부위에 일관된 전류를 공급함으로써 비침습적 시스템에서 발견되는 환자 순응도 문제를 극복합니다. 침습적 자극기는 특히 경골, 대퇴골, 상완골의 비골 유합에 적응증이 있으며, 요추 및 천골 고정술을 받는 고위험군 환자(고정술 실패 병력이나 흡연, 비만, 당뇨 등의 질환을 가진 환자 포함)에게 효과적임이 입증되었습니다. 뼈는 압전 물질이기 때문에 변형에 의해 미세한 전하를 발생시켜 치유를 돕습니다. 이러한 장치의 장점으로 인해 선진국에서 채택이 증가하고 있으며, 시장에서의 입지와 효과를 높이기 위한 연구가 진행되고 있습니다.
척추 고정과 뼈 재생에 있어 골형성 단백질(BMP)의 영향
형질전환 성장인자 베타(TGF-β) 계열의 골형성 단백질(BMP)은 특히 척추 고정술과 뼈 재생에 있어 자가 뼈 이식을 대체할 수 있는 유망한 대안으로, 2002년 FDA에서 요추 전방 고정술용으로 승인된 BMP는 기존 이식법보다 합병증이 적고 뼈의 치유를 촉진하는 것을 목표로 합니다. BMP는 장골 능선 이식편(ICBG)의 고정률 76%에 비해 98%의 높은 고정률을 보이며, 척추 간 고정, 후측방 고정, 원주 방향 고정 등 다양한 척추 고정술에 사용되고 있습니다. BMP는 FGF, PDGF, IGF와 같은 다른 생물학적 인자와 함께 뼈 재생을 촉진하는 데 중요한 역할을 하고 있으며, ICBG에 필적하며 척추 후방 고정술, 경추 고정술과 같은 적응증 외 사용으로 확대되고 있습니다. 자가 이식이 여전히 정형외과 수술의 표준이지만, BMP는 잘 연구되고 효과적인 대안을 제공합니다.
생체적합성 합성골이식편과 생물학적 제제의 채택 증가
생체적합성 합성골이식편과 생물학적 제제의 사용 증가는 뼈성장 제품 시장의 주요 촉진요인입니다. 세라믹, 폴리머, 복합재 등의 재료로 만들어진 합성 뼈 이식재는 천연 뼈 구조를 모방하여 새로운 뼈의 성장을 위한 발판을 제공하는 동시에 동종 이식편 및 자가 이식편과 관련된 질병 전파 및 면역 거부 반응의 위험을 줄입니다. 이러한 이식편은 특히 척추 고정술 및 외상 환자에서 수요가 많습니다. 골형성 단백질(BMP)과 혈소판풍부혈장(PRP)과 같은 생물학적 제제는 세포 활동과 뼈성장을 촉진하여 뼈의 자연 치유를 촉진하고, BMP는 골 형성을 유도하여 복잡한 골절의 결과를 개선하며, PRP는 치유를 촉진합니다. 이러한 기술 혁신은 뼈 손상 치료에 변화를 가져와 보다 효과적이고 효율적이며 개인화된 솔루션을 제공하고 있으며, 의료 서비스 제공자가 보다 안전하고 비용 효율적인 대안을 모색함에 따라 시장 성장을 촉진하고 있습니다.
산업 억제요인
급격한 기술 발전에 대한 대응
뼈성장 자극기는 비싸고 보험이 적용되지 않는 경우가 많기 때문에 많은 사람들이 물리치료, 아유르베다, 카이로프랙틱과 같은 저렴한 대체 요법을 찾게 됩니다. 이러한 대체의학은 높은 비용 효율성으로 인해 일본, 중국, 인도 등지에서 인기를 끌고 있습니다. 또한, 뼈 자극기로 인한 불편함과 정형외과 의사의 부족으로 인해 환자들은 전통적인 치료법을 찾게 됩니다. 인식 확대, 치료 접근성 개선, 보험 적용 확대는 중저소득 지역에서 뼈성장 제품의 채택을 촉진할 수 있습니다.
경쟁 상황
시장은 경쟁이 치열하며 Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet 등 세계 기업들이 인수, 제휴, 신제품 출시를 통해 시장을 주도하고 있습니다. 중소기업의 진입도 증가하고 있으며, 참신하고 비용 효율적인 제품으로 주목받고 있습니다. 특히 고령자 및 당뇨병 환자의 뼈 재생 문제를 해결하기 위해 펄스 전자기장 치료와 같은 첨단 뼈 치유 요법의 개발이 강조되고 있으며, Bioventus, Orthofix, Terumo와 같은 주요 기업들은 혁신적인 솔루션으로 제품 포트폴리오를 강화하고 있습니다.
주요 벤더
기타 유명 벤더
이 보고서는 세계 뼈성장 제품 시장을 조사 분석하여 각 지역의 수익과 예측, 전망과 기회, 경쟁 상황 등을 제공합니다.
The global bone growth products market is expected to grow at a CAGR of 3.72% from 2023 to 2029.
MARKET OPPORTUNITIES & DRIVERS
The Rise of Self-Powered Implantable Devices
Invasive bone growth stimulators are implantable devices that supply electrical energy to non-healing fractures or bone fusion sites, aiming to induce bone formation, stimulate growth, and promote healing. These devices, which use direct current delivered via an implanted lead, offer a consistent current to the fracture site, overcoming issues related to patient compliance seen in non-invasive systems. Invasive stimulators are particularly indicated for non-unions of the tibia, femur, and humerus and have proven effective for high-risk individuals undergoing lumbar or sacral fusion, including those with a history of fusion failure or conditions such as smoking, obesity, or diabetes. Bone, being a piezoelectric material, generates a small electrical charge under strain, which aids in healing. The growing advantages of these devices suggest increased adoption in developed countries, with ongoing research to enhance their market presence and efficacy.
Impact of Bone Morphogenetic Proteins (BMPs) in Spinal Fusion and Bone Regeneration
Bone morphogenetic proteins (BMPs), part of the transforming growth factor-beta (TGF-beta) family, have become a promising alternative to autologous bone grafts, especially in spinal fusion and bone regeneration. Approved by the FDA in 2002 for anterior lumbar fusion, BMPs aim to enhance bone healing with fewer complications than traditional grafting methods. They have shown high effectiveness, with fusion rates of 98% compared to 76% for iliac crest grafts (ICBGs), and are used in various spinal fusion techniques, including interbody, posterolateral, and circumferential fusion. BMPs are comparable to ICBGs in safety and efficacy and are expanding into off-label uses, such as posterior spinal fusion and cervical fusion. BMPs, alongside other biological factors like FGF, PDGF, and IGF, play a significant role in advancing bone regeneration. While autologous grafts remain the standard in orthopedic procedures, BMPs offer a well-researched, effective alternative.
The Rising Adoption of Biocompatible Synthetic Bone Grafts and Biologics
The growing use of biocompatible synthetic bone grafts and biologics is a key driver of the bone growth products market. Synthetic grafts, made from materials like ceramics, polymers, and composites, mimic natural bone structure, providing scaffolds for new bone growth while reducing disease transmission and immune rejection risks associated with allografts and autografts. These grafts are especially in demand for spinal fusion surgeries and trauma cases. Biologics, such as bone morphogenetic proteins (BMPs) and platelet-rich plasma (PRP), enhance natural bone healing by promoting cellular activity and bone growth. BMPs induce bone formation, improving outcomes in complex fractures, while PRP accelerates healing. These innovations are transforming the treatment of bone injuries, offering more effective, efficient, and personalized solutions, driving market growth as healthcare providers seek safer, cost-effective options.
INDUSTRY RESTRAINTS
Keeping Up with Rapid Technical Advancements
Bone growth stimulators are expensive and often not covered by insurance, leading many to seek affordable alternatives like physiotherapy, Ayurveda, and chiropractic care, especially in developing countries with high out-of-pocket costs. Due to their cost-effectiveness, these alternatives are popular in regions like Japan, China, and India. Additionally, discomfort from bone stimulators and a shortage of orthopedic surgeons drive patients toward traditional treatments. Expanding awareness, improving treatment access, and increasing insurance coverage could boost the adoption of bone growth products in low- and middle-income areas.
SEGMENTATION INSIGHTS
INSIGHTS BY PRODUCT
The global bone growth products market by product is segmented into bone growth stimulator devices, bone morphogenetic protein, and platelet-rich plasma. The bone growth stimulator devices segment accounted for the largest market share. Bone healing is a natural process, with the body continually replacing old bone with new. While fractures generally heal with appropriate treatments like casts, realignment, and surgery, complications such as delayed healing or non-union can occur. To address these issues, medical professionals seek ways to enhance and accelerate bone healing. Bone stimulators are designed to support this healing process and come in various forms, including electrical and ultrasonic stimulators. This segment dominates the market due to many patients preferring non-invasive or minimally invasive treatments to avoid surgical risks and long recovery periods. Bone growth stimulators, which can be used externally or with minimal intervention, align with this growing patient preference.
By Product
INSIGHTS BY APPLICATION
The global bone growth products market by application is categorized into spinal fusion surgeries, oral & maxillofacial surgeries, delayed union & non-union bone fractures, and others. The spinal fusion surgeries show the highest growth during the forecast period. Bone Growth Stimulation (BGS) is a therapeutic technique commonly prescribed by surgeons following spinal fusion procedures to enhance the healing of bones in the spine. A bone growth stimulator is often used for patients undergoing cervical (neck) or lumbar (low back) spine surgeries to promote spinal fusion. This device helps to improve bone healing by stimulating growth and is particularly beneficial in cases where the fusion process is delayed or fails. Studies have shown that BGS significantly enhances fusion outcomes in both cervical and lumbar regions, making it a popular choice for post-operative treatment, thus helping segmental growth.
By Application
INSIGHTS BY END-USER
Based on the end-user, the hospitals & clinics segment holds the largest global bone growth products market share. Hospitals serve as the primary point of care for bone-related issues, often investing in advanced technologies and materials to improve treatment outcomes. However, only larger multispecialty and Tier-I hospitals provide cutting-edge treatments such as bone morphogenetic proteins (BMP) and platelet-rich plasma (PRP). This is due to the complexity and cost of these therapies. Increasing patient awareness and improved insurance coverage have fueled the demand for advanced treatments, including bone stimulators, BMP, and PRP, which are particularly effective for treating difficult fractures like non-union fractures. Physician offices and clinics, especially in remote areas, are many patients' first point of contact. While these facilities may not be able to offer advanced treatments, they play a crucial role in referring patients to larger, specialized hospitals, which are helping the market grow.
By End-User
GEOGRAPHICAL ANALYSIS
North America accounted for the largest global bone growth products market share, followed by Europe. The U.S. remains a major revenue contributor in North America due to the high penetration of spinal fusion procedures and a considerable volume of spinal fusion and non-fusion surgeries. The increasing prevalence of orthopedic diseases, accidental injuries, and the aging population primarily drive the growth. The availability of advanced, safer, and minimally invasive surgical treatments and ongoing technological innovations further support market expansion.
In Europe, Germany, France, the UK, Italy, and Spain are the primary revenue contributors to the global bone growth products market. This region benefits from a well-established and sophisticated healthcare infrastructure, providing access to advanced medical services, including spinal fusion and non-fusion procedures. The market's growth is driven by the increasing prevalence of bone disorders and the availability of reimbursement coverage for spinal fusion surgeries across many European countries.
By Geography
COMPETITIVE LANDSCAPE
The global bone growth products market report includes exclusive data on 30 vendors. The market is highly competitive, with global players like Medtronic, Johnson & Johnson, Stryker, and Zimmer Biomet leading through acquisitions, collaborations, and new product launches. Small and mid-sized companies increasingly enter the market, focusing on novel, cost-effective products. There is a growing emphasis on developing advanced bone healing therapies, such as pulsed electromagnetic field therapies, to address challenges in bone regeneration, especially for elderly and diabetic patients. Key players like Bioventus, Orthofix, and Terumo are enhancing their product portfolios with innovative solutions.
Key vendors
Other Prominent Vendors
KEY QUESTIONS ANSWERED:
CHAPTER - 1: Bone Growth Products Market Overview
CHAPTER - 2: Bone Growth Products Market
CHAPTER - 3: Bone Growth Products Market Segmentation Data
CHAPTER - 4: Key Regions Overview
CHAPTER - 5: Bone Growth Products Market Prospects & Opportunities
CHAPTER - 6: Bone Growth Products Industry Overview
CHAPTER - 7: Appendix